Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M5,896Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M164EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.2Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.4PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M42,861,049ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with VHT

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

VHT is held by these investors:

VHT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481351.05view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94712.04view
DINWOODIE, TYLER WAYNE PAULSenior Officer 2017-01-16Buy4,000$0.1780817.65view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.3610014.71view
Bebek, IvanDirector 2017-01-16Buy8,990$3.383969.82view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4133451.22view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91392.87view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.272093.94view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38127.82view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1591606.67view

Quarterly/Annual Reports about VHT:

    News about VHT:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Goldman Sachs and the Proposed Repeal of Obamacare Feb 21 2017
    Pulling Back the Curtain on Danaher’s 4Q16 Operating Performance Feb 02 2017
    Gilead Sciences Initiated Phase 3 Trials to Evaluate Filgotinib Feb 01 2017
    Merck & Co.’s 4Q16 Estimates: Expect Flat Revenues Jan 31 2017
    What Recent Developments Could Drive Eli Lilly’s Growth? Jan 27 2017
    3 ETFs to Buy If You're Impressed With Johnson & Johnson's Fourth Quarter Jan 24 2017
    Exploring Bristol-Myers Squibb’s Oncology Segment in 4Q16 Jan 24 2017
    Why health-care stocks aren’t moving after President Trump’s Obamacare executive order Jan 24 2017
    Can Q4 Earnings Revitalize Healthcare ETFs? Jan 23 2017
    What to Expect from Johnson & Johnson’s 4Q16 Earnings Jan 19 2017
    Is the 2017 Outlook for Healthcare Optimistic? Jan 03 2017
    New Products, Recent Developments for Gilead Sciences Jan 02 2017
    Edwards Lifesciences Sees Growth on Long-Term Growth Strategy Dec 15 2016
    Johnson & Johnson’s Financial Guidance for 2016 Dec 13 2016
    David Einhorn’s Investment Guidance at the Robin Hood Conference Dec 07 2016
    Why Merck’s Immunology Business Matters Now Dec 05 2016
    [$$] Gearing Up for Growth in the Trump Era Dec 03 2016
    Recent R&D Developments from Merck You Won’t Want to Miss Dec 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)